2026-07-21T15:38:45Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/230342024-11-28T22:45:34Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud author Bullon-Vela, Vanessa author Abete, Itziar author Tur, Josep A author Konieczna, Jadwiga author Romaguera, Dora author Pinto, Xavier author Corbella, Emili author Martinez-Gonzalez, Miguel A author Sayon-Orea, Carmen author Toledo, Estefanía author Corella, Dolores author Macias-Gonzalez, Manuel author Tinahones, Francisco J author Fito, Montserrat author Estruch, Ramon author Ros, Emilio author Salas-Salvado, Jordi author Daimiel, Lidia author Mascaró, Catalina M author Zulet, Maria Angeles author Martinez, Jose Alfredo author PREDIMED-Plus Investigators 2024-09-13T09:15:57Z 2024-09-13T09:15:57Z 2020-10 Bullon-Vela V, Abete I, Tur JA, Konieczna J, Romaguera D, Pinto X, et al. Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications. Ther Adv Endocrinol Metab. 2020 Oct;11:1-15. 10.1177/2042018820958298 2042-0196 2042-0188 Therapeutic Advances in Endocrinology and Metabolism http://hdl.handle.net/20.500.13003/9225 33149882 L2007069843 2-s2.0-85093933092 https://hdl.handle.net/20.500.12105/23034 586583200001 Background: Visceral adipose tissue (VAT) has a hazardous influence on systemic inflammation, insulin resistance and an adverse metabolic profile, which increases the risk of developing non-alcoholic fatty liver disease (NAFLD) and chronic complications of diabetes. In our study we aimed to evaluate the association of VAT and the triglyceride glucose (TyG) as a proxy of insulin resistance surrogated with metabolic and liver risk factors among subjects diagnosed with metabolic syndrome (MetS). Methods: A cross-sectional study was performed including 326 participants with MetS (55-75 years) from the PREDIMED-Plus study. Liver-status markers, VAT and TyG were assessed. Participants were stratified by tertiles according to VAT (n = 254) and TyG (n = 326). A receiver operating characteristic curve was used to analyse the efficiency of TyG for VAT. Results: Subjects with greater visceral fat depots showed worse lipid profile, higher homeostatic model assessment for insulin resistance (HOMA-IR), TyG, alanine transaminase (ALT), fibroblast growth factor-21 (FGF-21), fatty liver index (FLI) and hepatic steatosis index (HSI) compared with participants in the first tertile. The multi-adjusted linear-regression analyses indicated that individuals in the third tertile of TyG (>9.1-10.7) had a positive association with HOMA-IR [beta = 3.07 (95% confidence interval (CI) 2.28-3.86; p trend < 0.001)], ALT [beta = 7.43 (95% CI 2.23-12.63; p trend = 0.005)], gamma glutamyl transferase (GGT) [beta = 14.12 (95% CI 3.64-24.61; p trend = 0.008)], FGF-21 [beta = 190.69 (95% CI 93.13-288.25; p trend < 0.001)], FLI [beta = 18.65 (95% CI 14.97-22.23; p trend < 0.001)] and HSI [beta = 3.46 (95% CI, 2.23-4.68; p trend < 0.001)] versus participants from the first tertile. Interestingly, the TyG showed the largest area under the receiver operating curve (AUC) for women (AUC = 0.713; 95% CI 0.62-0.79) compared with men (AUC = 0.570; 95% CI 0.48-0.66). Conclusions: A disrupted VAT enlargement and impairment of TyG are strongly associated with liver status and cardiometabolic risk factors linked with NAFLD in individuals diagnosed with MetS. Moreover, the TyG could be used as a suitable and reliable marker estimator of VAT. eng Insulin resistance Metabolic syndrome non-alcoholic fatty liver disease Triglyceride glucose index Visceral adipose tissue Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications research article